Northwest Biotherapeutics, Inc.
NWBio is developing DCVax® dendritic cell-based therapeutic vaccines. The Company’s DCVax®-L for resectable solid tumors is nearing completion of a 331-patient Phase III trial for newly diagnosed GBM, and various potential Phase II trials are anticipated in the future, including in combination with checkpoint inhibitor drugs. The Company’s DCVax®-Direct for inoperable solid tumors has completed a 40-patient Phase I trial for diverse cancers, and various potential Phase II trials are anticipated.